KIKA Clinical Solutions Advanced EDC Platform for Clinical Asset Management Used by SORIN Group on Heart Valve Studies

BOSTON--(BUSINESS WIRE)--KIKATM Clinical Solutions announced that SORIN Group is using KIKA's advanced EDC platform for clinical trial asset management on two open observational, multi-center, Real Life Registries to evaluate the effectiveness of SORIN Heart Valves.

KIKA provides the VeracityTM advanced EDC platform for Clinical Asset ManagementTM to the pharmaceutical, biotechnology and medical device industries.

SORIN Group is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,600 employees worldwide, the Group focuses on three major therapeutic areas: cardiopulmonary bypass; cardiac rhythm management; and, heart valve repair and replacement.

KIKA CEO Linda Beneze said, "We're pleased that SORIN has continued to work with KIKA for their clinical trial needs and we're excited that they now have the opportunities VeracityTM offers to collect, protect and maximize their most important clinical asset - their data."

About KIKA Clinical Solutions

KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's VeracityTM is the leading-edge, Web-based clinical trial software platform that delivers Clinical Asset ManagementTM for any size clinical trial. VeracityTM is configured to meet study needs precisely, with unmatched flexibility and advanced EDC capabilities including images and online adjudication to meet the most complex workflow requirements. VeracityTM is backed by the industry's most reliable IT infrastructure, a world-class Professional Services organization, and ISO-certified processes. For more information, visit www.kikaclinicalsolutions.com, or call 1-617-619-9990 in the U.S.; +33 (0)1 53 17 95 in Europe; or email [email protected]

Follow KIKA on Facebook and on Twitter as kikaclinical.

KIKA, Veracity and Clinical Asset Management are trademarks of the KIKA group of companies.

 

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.